About Us

Biograil™ was established in 2019 and is a spin-off from Egalet/Zyla Life Sciences. Biograil™ is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD™ technology to unlock the potential of transforming markets of injectable pharmaceutical products into convenient oral capsules.

the Team

Karsten Lindhardt
Chief Executive Officer & Founder

Nikolaj Skak
Chief Technology Officer & Founder

Kamille Dumong Erichsen
Non-Clinical Project Director

Nils Piwon
Portfolio & Alliance Director

Lars Hellerung Christiansen
Advisor Business Development & Founder

John M. Barberich
Consulting Chief Financial Officer & Founder

Karsten Lindhardt, CEO

20+ years in pharmaceutical industry, Co-founder, Director Scantox ApS, Head of R&D and CSO Egalet, senior positions in Novo Nordisk, Ferring, Prosidion & Curalogic

Nikolaj Skak, CTO

15+ years in pharmaceutical industry, Head of Pharmaceutical Development Egalet, senior positions in Veloxis

Kamille Dumong Erichsen, Non-Clinical Project Director

20+ years in pharmaceutical industry, senior positions in Savara, Roche, Santaris, TopoTarget

Nils Piwon, Portfolio & Alliance Director

20+ years in pharmaceutical industry, Executive Director of Clinical Research, PRA Health Sciences, Director PM and RS at Parexel

Lars Hellerung Christiansen, Advisor BD

30+ years of experience as serial entrepreneur, Co-founder Symphogen , ACADIA, Zealand Pharm, and others

John M. Barberich: Consulting CFO

30+ years of experience in biotech and investing, Co-founder, Chairman, Biograil ApS; Co-founder, Director, Scantox ApS; Co-founder and former CFO, ACADIA Pharmaceuticals; Co-founder and director, Pluromed, Co-founder and CEO, FX Therapeutics, CFO Omrix, Venture Partner, Nordic Biotech, Transaction Executive with The Henley Group and CPA/Manager, PWC

the Investors

Biograil ApS
Baldersbuen 2
2640 Hedehusene

E: info@biograil.com

CVR/VAT: DK-40666699